Skip to main content
Clinical Trials/NCT02094118
NCT02094118
Completed
Phase 1

Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

Mayo Clinic2 sites in 1 country171 target enrollmentJanuary 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Blood Transfusion Complications
Sponsor
Mayo Clinic
Enrollment
171
Locations
2
Primary Endpoint
Biomarkers Associated With Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study is designed to determine if point-of-care washing of allogeneic Leukocyte-Reduced Red Blood Cells reduces pulmonary complications when compared to standard-of-care Leukocyte-Reduced Red Blood Cells in a cardiac surgical population.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
May 30, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Daryl J. Kor, M.D.

Associate Professor of Anesthsiology

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Age equal to or greater than 18 years of age.
  • Scheduled to have cardiac bypass surgery at Mayo Clinic in Rochester, Minnesota or Duke University Medical Center in Durham, North Carolina
  • At risk for needing at least 4 units of blood during/after surgery

Exclusion Criteria

  • Emergency surgery
  • Immunoglobulin A (IgA) deficiency
  • History of severe recurrent transfusion reactions
  • Refusal to receive allogeneic blood products
  • Refusal to provide informed consent
  • Prevalent lung injury prior to randomization
  • Prevalent congestive heart failure prior to randomization
  • Expected hospital stay \< 48 hours
  • Not anticipated to survive \> 48 hours
  • Previously enrolled in this trial

Outcomes

Primary Outcomes

Biomarkers Associated With Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload.

Time Frame: 18 hours after the initiation of the first red blood cell transfusion.

This panel of biomarkers measures inflammation, altered coagulation, and endothelial activation all of which play key roles in the pathogenesis of lung injury.

Number of "Off-protocol" Transfusions

Time Frame: Day of surgery. Approximately 1 day.

The number of standard issued red blood cell units that were transfused to study participants in the washed red blood cell arm of the trial. Additionally, emergency red blood cell transfusions in the standard issued arm of the trial that were administered outside of the study protocol were also included to the definition of "off protocol" transfusion.

Change in Recipient Hemoglobin

Time Frame: Pre to 6 hours post transfusion

Change in Hemoglobin from pre-transfusion to post-transfusion

Change in Recipient Cell Free Hemoglobin(CFH)

Time Frame: Pre transfusion until study day 5 or hospital discharge, approximately 5 days

Change in CFH from pre-transfusion to worst (highest/maximum) post-transfusion

Change in Haptoglobin

Time Frame: Pre transfusion to study day 5 or hospital discharge, approximately 5 days

Change in Haptoglobin from pre-transfusion to worst (minimum) post-transfusion

Secondary Outcomes

  • Duration of Mechanical Ventilation(Up to hospital day 28, or discharge, whichever comes first)
  • Duration of Oxygen Supplementation(Up to day 28, or hospital discharge, whichever comes first)
  • Sequential Organ Failure Assessment (SOFA) Score(Through postoperative day 5.)
  • Hospital Length of Stay(Up to day 28)
  • Post Transfusion Respiratory Complications.(Up to day 28)

Study Sites (2)

Loading locations...

Similar Trials